Approach to Milestone Regression

79
APPROACH TO MILESTONE REGRESSION DR. PIYUSH OJHA DM RESIDENT DEPARTMENT OF NEUROLOGY GOVT MEDICAL COLLEGE, KOTA

Transcript of Approach to Milestone Regression

Page 1: Approach to Milestone Regression

APPROACH TO MILESTONE REGRESSION

DR. PIYUSH OJHADM RESIDENT

DEPARTMENT OF NEUROLOGYGOVT MEDICAL COLLEGE, KOTA

Page 2: Approach to Milestone Regression

DEVELOPMENTAL REGRESSION• Delayed achievement of developmental milestones is one of

the most common problems evaluated by child neurologists.

• Two important questions : – Is developmental delay restricted to specific areas, or is it

global?– Is development delayed or regressing?

• Loss of developmental milestones previously attained usually indicates a progressive disease of the nervous system.

Page 3: Approach to Milestone Regression

• The Denver Developmental Screening Test - an efficient and reliable method for assessing development.

• Rapidly assesses 4 different components of development:• Personal- Social• Fine motor adaptive• Language and • Gross motor.

Page 4: Approach to Milestone Regression
Page 5: Approach to Milestone Regression

• A progressive deterioration of neurological functions - loss of speech, vision, hearing or locomotion ,often associated with seizure, feeding and intellectual impairment.

• Neuroregressive / Neurodegenerative Disorders - a group of heterogeneous diseases which results from specific genetic, biochemical defect, chronic viral infection and toxic substances.

• May involves both the gray matter and white matter

Page 6: Approach to Milestone Regression

Normal Development

Static Encephalopathy

Regression

Illness/trauma

Page 7: Approach to Milestone Regression

“PSEUDO-REGRESSION”• Increasing spasticity• New-onset movement disorder• New-onset seizures• Worsening of previous seizures/ NCSE• Severe malnutrition• Systemic illness• Progressive hydrocephalus• Parental misperception of attained milestones• Side effects of drugs• Emotional deprivation• Emotional problems: depression

Page 8: Approach to Milestone Regression

APPROACH TO A CHILD WITH MILESTONE REGRESSION

Page 9: Approach to Milestone Regression

IMPORTANT CONSIDERATION

• Regression AND NOT Delay ????

• Age above 2 Years OR Less than 2 Years ???

• Is only the Central nervous system involved, or are other organs involved? – Other organ involvement suggests lysosomal, peroxisomal,

and mitochondrial disorders.

Page 10: Approach to Milestone Regression

IMPORTANT CONSIDERATIONS• Are the clinical features referable only to the central nervous

system or to both the central and peripheral nervous systems? – Nerve or muscle involvement suggests mainly lysosomal

and mitochondrial disorders.

• Does the disease affect primarily the gray matter or the white matter?– Early features of

• Gray matter disease - personality change, seizures, and dementia/cognitive decline.

• White matter disease - Focal neurological deficits, spasticity, and blindness.

– Whether the process begins in the gray matter or white matter, eventually clinical features of dysfunction develop in both.

Page 11: Approach to Milestone Regression

Fenichel’s Clinical Pediatric Neurology 7th edition

Page 12: Approach to Milestone Regression

Fenichel’s Clinical Pediatric Neurology 7th edition

Page 13: Approach to Milestone Regression

Fenichel’s Clinical Pediatric Neurology 7th edition

Page 14: Approach to Milestone Regression

Differentiatingfeatures

White matterdisorders

Gray matterdisorders

Age of onset Usually late (childhood) Usually early (infancy)

Head size May have megalenchepaly

Usually microcepaly

Seizures Late , rare Early, severe

Cognitive functions Initially normal Progressive dementia

Peripheral neuropathy Early demyelination Late, axonal loss

Spasticity Early, severe Later, progressive

Reflexes Absent(neuropathy) or exaggerated(long tracts)

Normal or exaggerated

Page 15: Approach to Milestone Regression

Differentiatingfeatures

White matterdisorders

Gray matterdisorders

Cerebellar signs Early, prominent late

Fundal examination May show optic atrophy Retinal degeneration

EEG Diffuse delta slowing Epileptic form discharges

EMG Slowed nerve conduction velocity

Usually normal

Evoked potentials(VEP, ABR)

Prolonged or absent Usually normal

ERG Normal Abnormal

Page 16: Approach to Milestone Regression

CLASSIFICATION OF NEURODEGENERATIVE DISORDERS

Inherited Acquired

Both

White matter

Gray matter Metabolic

Infections

Page 17: Approach to Milestone Regression

ACQUIRED CAUSES

Infections

SSPE

Progressive Rubella

Syndrome

Toxoplasma (8% cases)

Chronic HIV infection

Metabolic

Chronic lead poisoning

Hypothyroidism

Vit B-12 & E deficiency

Page 18: Approach to Milestone Regression

INHERITED CAUSES• Gray matter involvement : A. Gray matter involvement with visceromegaly

– GM1 Gangliosides-Infantile , generalized , juvenile– Sandholf disease – Niemann pick Disease – MPS– Gaucher disease– Sialidosis

Page 19: Approach to Milestone Regression

B. Gray matter diseases involvement without visceromegaly

– Tay Sach disease – Rett Syndrome– Neuronal ceroid lipofuscinosis– Menke’s kinky hair disease

Page 20: Approach to Milestone Regression

WHITE MATTER INVOLVEMENT

Leukodystrophies– Metachromatic leukodystrophy– Krabbe disease– Adrenoleukodystrophy– Alexander disease

Page 21: Approach to Milestone Regression

OBJECTIVE OF EVALUATION• Confirmation of Developmental regression• Categorization of domains involved• Identification of possible underlying etiology• Referral to appropriate rehabilitation services• Management of associated co-morbidities

• Multidisciplinary approach• Counselling

Shevell, 1998

Page 22: Approach to Milestone Regression

• Birth history:

– Term/preterm

– Postnatal complications

• Meningitis

• Head trauma

• kernicterus

Page 23: Approach to Milestone Regression

• Developmental history:– Detailed development history- decide whether there is

delayed development milestones or regression of milestones

• Family history:– Family history of neurological disorder– Early or unexplained death– Nature of the neurological manifestations should be

clarified• H/o of consanguinity - ethnic heritage

– Origin from same village– Same last names

Page 24: Approach to Milestone Regression

• Gestational history– Prior pregnancies/ abortions/ Early postnatal deaths– Adverse perinatal events – hypoxia/hypoglycemia– Delivery details– Apgar, birth weight– Duration of hospital stay/ difficulties in Nutrition– Possible neonatal encephalopathy : seizures, feeding

difficulty, obtundation

Page 25: Approach to Milestone Regression

• Developmental history– First domain of concern– Timing of milestones– Loss/regression– Current skill level in domains– Degree of independence in daily activities– Scholastic performance; special needs

• Coexisting medical problems• Past medical history; treatment• Social history• Access to rehabilitation

Page 26: Approach to Milestone Regression

CLINICAL EXAMINATION• General physical examination

– Dysmorphism: Mitochondrial disorders, Neonatal adrenal leukodystrophy ,coarse facial features (MPS)

– Occipito-Frontal Circumference –• Microcepaly (gray matter disease)• Megalenchepaly – certain white mater

disorder(Cannavan & Alexander)– Jaundice– Enlarged tongue

Page 27: Approach to Milestone Regression

• Skin & hair ( Hartnup Diseases-pellagra like skin rash, Menkes disease-kinky hair)

• Examination of the spine- for associated complications (scoliosis)

• Contractures of joints• Systemic examination:

– Hepatosplenomegaly– Chest deformity– Cardiomyopathy

Page 28: Approach to Milestone Regression

NEUROLOGICAL EXAMINATION• Higher mental function, signs of raised ICP• Speech, memory• Cranial nerves• Motor system:

– Tone– Deep tendon reflexes

• Sensory loss /neuropathy• Abnormal /involuntary movements• Gait

Page 29: Approach to Milestone Regression

EYE EXAMINATION

• Optic atrophy (white matter- due to demyelination)

• Retinal degeneration (gray matter)- as the retinal receptors

are neuronal cells): Cherry red spot, retinitis pigmentosa

• Cataracts

• Telengiectasias

• K.F ring

Page 30: Approach to Milestone Regression

INVESTIGATIONS

• To identify the underlying diagnosis & associated

complications

• CBC- pancytopenia, vacuolated lymphocytes, acanthocytes

• ABG - metabolic acidosis(organic acidopathies, urea cycle

defects, mitochondrial encephalopathies)

• Electrolytes (Anion gap), for adrenal insufficiency

(adrenoleukodystrophy)

• Ammonia level, LFTs, RFTs

Page 31: Approach to Milestone Regression

• Special tests:

– Lactate & pyruvate levels, Lysosomal enzyme level

– WBCs, Fibroblast enzyme level

– Wilson’s disease-serum ceruloplasmin level, serum copper

– Amino acids

– Urinary organic acids

Page 32: Approach to Milestone Regression

• Urine– Reducing substances, Organic acids,24 hr (MPS)

• Imaging– Skull & Vertebrae, Long bones– CT/MRI

• Biopsy– Skin, Bone marrow, nerve, brain

• Diagnosis– Important for genetic counseling

• Outcome - Prognosis poor

Page 33: Approach to Milestone Regression

BELIEVE IN HISTORY AND EXAMINATION !!! (GLOBAL DEVELOPMENTAL DELAY AND REGRESSION)

Page 34: Approach to Milestone Regression

MANAGEMENT• Directed towards the treatment of the underlying disorder,

other associated features and complications• Supportive : The treatable complications :

• feeding difficulties, Gastoresophageal reflux• spasticity, drooling• skeletal deformities, and recurrent chest infections• epilepsy, sleep disorder, behavioral symptoms

• A multidisciplinary approach (Pediatrics, neurology, genetics, orthopedics, physiotherapy, and occupational therapy).

Page 35: Approach to Milestone Regression

SPECIFIC TREATMENTNeurodegenerativedisorders

Specific treatment modality

Krabbe leukodystrophy Bone marrow transplantation

Metachromatic leukodystrophy Bone marrow transplantation

Adrenoleukodystrophy Glyceryl trioleate and trierucate,steroids for adrenal insufficiency, diet low in VLCFA, bone marrow transplantation

Mucopolysaccharidosis Bone marrow transplantation,recombinant human α-L-iduronidase

Menkes kinky hair syndrome Copper sulfate

Page 36: Approach to Milestone Regression

Neurodegenerativedisorders

Specific treatment modality

Mitochondrial encephalopathies Nicotinamide, riboflavin,dichloroacetate, L-carnitine, CoQ10

Wilson disease D- penicillamine, trietine, zinc acetate,liver transplantation

Refsum disease Reduction of phytanic acid intake

Lesch-Nyhan disease Allopurinol

Fabry’s Disease Recombinant human α galactosidase A

Page 37: Approach to Milestone Regression

Guanidinoacetate Methyltransferase Deficiency

• Rare but treatable disorder • Amidinotransferase converts glycine to guanidinoacetate and

guanidinoacetate methyltransferase converts guanidinoacetate to creatine.

• Autosomal recessive inheritance (19p13.3)• Affected children appear normal at birth and may develop

normally during infancy. • By the end of the first year, development fails to progress and

hypotonia is noted. • Regression of development follows and is associated with

dyskinesias, dystonia, and myoclonic jerks.

Page 38: Approach to Milestone Regression

• MRI -marked demyelination• MR Spectroscopy - creatine depletion and guanidinoacetate

phosphate accumulation.

• Management - Early oral administration of creatine monohydrate significantly prevents and reverses all symptoms, and late treatment provides some reduction of abnormal movements.

Page 39: Approach to Milestone Regression

• Main defect - almost complete deficiency of the enzyme cystathionine- b -synthase (Picker and Levy, 2006).

• Two variants – – B 6 - responsive & – B 6 –nonresponsive

• AR inheritance

HOMOCYSTINURIA

Page 40: Approach to Milestone Regression

HOMOCYSTINURIA

• Affected individuals appear normal at birth. • Neurological features - mild to moderate MR, ectopia lentis,

and cerebral thromboembolism. • Developmental delay ( 50% cases) and intelligence declines

progressively with age in untreated children. • Most eventually function in the mildly retarded range.• Intelligence generally higher in B 6 –responsive cases.• Thromboembolism - first clue to the diagnosis in 15% cases.• The presence of either thromboembolism or lens dislocation

strongly suggests homocystinuria.

Page 41: Approach to Milestone Regression

HOMOCYSTINURIA• Diagnosis - increased concentrations of plasma homocystine,

total homocysteine, and methionine; increased concentration of urine homocystine; and reduced cystathionine b-synthase enzyme activity.

• Molecular genetic diagnosis available.• Management. Challenge all patients with Pyridoxine (vitamin

B 6 ) before starting treatment.• IF responsive – Pyridoxine (200 mg/day)• IF Not responsive - still receive doses of 100 to 200 mg/day. • All patients - protein-restricted diet. • Treatment with betaine, 5 to 10 g/day in two divided doses,

provides an alternate remethylation pathway to convert excess homocysteine to methionine.

Page 42: Approach to Milestone Regression

Krabbe disease (Globoid Cell Leukodystrophy) Autosomal Recessive Galactosylceramide b -galactosidase deficiency Myelin loss & presence of globoid bodies in white matter EARLY ONSET VARIANT : Symptom appear by 6 months◦ Irritability Vomiting ◦Bouts of hyperpyrexia Progressive hypertonicity

Startle Myoclonus, Seizures UMN signs with areflexia

Within 2 to 4 months, the infant is in a permanent position of opisthotonos, and all previously achieved milestones are lost.

Blindness occurs, and before 1 year, 90% of these infants are either dead or in a chronic vegetative state.

Page 43: Approach to Milestone Regression

Krabbe disease (Globoid Cell Leukodystrophy) LATE ONSET VARIANT : Neurological deterioration usually begins at 2-6 yrs. May start as early as the second year or as late as

adolescence. Major features - Mental regression, cortical blindness, and

generalized or unilateral spasticity. Initial feature may be progressive spasticity rather than

dementia. Unlike the infantile form, peripheral neuropathy is not a

feature of the juvenile form. Progressive worsening -> a vegetative state.

Page 44: Approach to Milestone Regression

Krabbe disease Investigations◦MRI – diffuse demyelination◦ Leukocyte & Skin fibroblast enzyme level◦ CSF Protein : Early variety – elevated

Late Onset Variety - Normal ◦Motor NCV: Markedly prolonged latencies

Management - Hematopoietic stem cell transplantation slows the course of disease in children with infantile-onset Krabbe disease diagnosed before symptom onset.

Neurological manifestations may reverse.

Page 45: Approach to Milestone Regression

TAY SACHS DISEASE

• N-acetyl- b -hexosaminidase deficiency • Intralysosomal storage of the glycosphingolipid GM 2

ganglioside.

• Complete deficiency - Tay-Sachs disease• CNS – the only affected organ. • Partial deficiencies cause the juvenile and adult forms of GM 2

gangliosidosis.

Page 46: Approach to Milestone Regression

TAY SACHS DISEASE• Typical initial symptom - between 3-6 months - an abnormal

startle reaction (Moro reflex) to noise or light. • Motor regression begins between 4 and 6 months of age. • The infant comes to medical attention because of either

delayed achievement of motor milestones or loss of milestones previously attained.

• Cherry-red spot on macula present in almost every patient (NOT Pathognomic)

• By 1 year - infant is severely retarded, unresponsive, and spastic.

• 2nd year - the head enlarges and seizures develop. • Most children die by 5 years of age.

Page 47: Approach to Milestone Regression

JUVENILE VARIANT :- • Often begins with ataxia and incoordination between 2 and 10

years of age. • Speech, life skills, and cognition decline. • Spasticity and seizures present by end of 1st decade• Loss of vision occurs much later than infantile form.• Cherry-red spot not a consistent finding.• Optic atrophy and retinitis pigmentosa occur late.• A vegetative state with decerebrate rigidity by 10-15 years.• Followed by death, usually due to infection. • Sometimes may follow a aggressive course, culminating in

death in 2 to 4 years.

Page 48: Approach to Milestone Regression

TAY SACHS DISEASE• Diagnosis - Suspect the diagnosis in any Jewish child with

psychomotor retardation and a cherry-red spot on the macula.

• Demonstration of absent to nearly absent b -hexosaminidase A enzymatic activity in the serum or white blood cells or Fibroblast.

• Mutation analysis identifies the carrier state.

• Management - Treatment is supportive.

Page 49: Approach to Milestone Regression

Gaucher disease Commonest AR inheritance (Chr 1q21) Deficiency of Glucocerebrosidase 5 types ◦ Type 1 – Perinatal lethal form – spares Brain◦ Type 2 – onset < 2 years, rapidly progressive course

by 2-4 years◦ Type 3 – onset > 2 years, slowly progressive course with longer survival◦Type 4 ◦Type 5 – cardiovascular form

Page 50: Approach to Milestone Regression

Gaucher disease type 2 – symptom onset usually < 6 months• Initial features – motor regression and cranial nerve

dysfunction. • Children are first hypotonic and then spastic.• Head retraction - an early and characteristic sign - probably

due to meningeal irritation.• Difficulties in sucking and swallowing, trismus, and

oculomotor palsies are typical. • Mental deterioration is rapid , seizures uncommon.• Splenomegaly >> hepatomegaly, jaundice not expected.• Hypersplenism - anemia, thrombocytopenia, and leukopenia.• Death usually occurs during the first year and always by the

second.

Page 51: Approach to Milestone Regression

Gaucher disease type 3 – • Age of onset – early childhood to adulthood• Hepatosplenomegaly usually precedes neurological

deterioration. • MC neurological manifestations - seizures and mental

regression (mild memory loss to severe dementia)• Myoclonus and myoclonic seizures present in many patients.• Combination of spasticity, ataxia, and cranial nerve

dysfunction may be present. • Vertical oculomotor apraxia, as described in Niemann-Pick

disease, may occur in late-onset Gaucher disease as well.

Page 52: Approach to Milestone Regression

• Diagnosis – – Assay of acid b –glucosylceramidase enzyme activity in

peripheral blood leukocytes or hepatocytes– Gaucher cells in bone marrow - pathognomic

• Management - Symptomatic treatment includes partial or total splenectomy, blood transfusion, analgesics and supplemental treatment such as oral bisphosphonates for severe osteopenia.

• Type 3 disease - may benefit from bone marrow transplantation to correct the metabolic defect.

• Enzyme replacement therapy, using Imiglucerase (CEREZYME), is effective in reversing the hematological and liver/spleen involvement BUT NOT NEUROLOGICAL SYMPTOMS.

Page 53: Approach to Milestone Regression

Bone marrow smear showing Gaucher cell. The cytoplasm has a fibrillary and striated appearance with nuclei small and eccentric in location MGG ×100

Page 54: Approach to Milestone Regression

Mucopolysaccharidosis Absence of variety of lysosomal hydrolases involved in the

catabolism of dermatan sulfate, heparan sulfate, or keratin sulfate.

Defective degradation of Mucopolysacharides

7 types recognised – Type 1,2,3 and 7 affect nervous system

Multisystem involvement Coarse facial features , Dwarfism , Kyphoscoliosis Macrocephaly, with or without communicating hydrocephalus Hepatosplenomegaly , Cardiovascular abnormalities Hearing loss , contractures

Page 55: Approach to Milestone Regression

Mucopolysaccharidosis Type 1 & 3 – onset in infancy Type 2 & 7 – onset after > 2 yrs of normal development Type 2 – Hunter syndrome (X linked inheritance)- deficient

Iduronate Sulfatase

Diagnosis : - ◦Mucopolysacchariduria with equal excretion of dermatan

sulfate and heparan sulfate◦ enzyme deficiency in cultured fibroblasts or serum.

Enzyme replacement therapy with Aldurazyme, licensed for treatment of the non–CNS manifestations of MPS I, improves liver size, growth, joint mobility, breathing, and sleep apnea.

Page 56: Approach to Milestone Regression

Niemann-Pick Disease Type C Onset is usually after age 2 with slow progression. AR inheritance Early development is normal. Mean age of onset = 3 years Cerebellar ataxia or dystonia is initial feature Apraxia of vertical gaze and cognitive difficulties follow (6yrs) Vertical gaze apraxia always suggests Niemann-Pick disease

type C. Relentless progressive neurological degeneration. Dementia, seizures, and spasticity cause severe disability

during the 2nd decade. Impaired cholesterol esterification and positive filipin staining

in cultured fibroblasts confirm the diagnosis.

Page 57: Approach to Milestone Regression

Inherited white matter disease

Defect in myelin synthesis

Involves brain, spinal cord and peripheral nerves.

Classic dysmyelinating disorders are

Adrenoleukodystrophy, Metachromatic Leucodystrophy,

Krabbe's disease

Leukodystrophy

Page 58: Approach to Milestone Regression

Metachromatic leukodystrophy Autosomal Recessive Arylsulfatase A deficiency deficiency Infantile (50-60% cases) and Juvenile variety(20-30%) Age at onset within a family usually similar. All individuals eventually lose motor and intellectual

functions. The disease course - 3 to 10 or more years in the late-

infantile-onset form and as long as 20 years or more in the juvenile- and adult-onset forms.

Death – due to pneumonia or other infection. Treatment is mainly supportive .

Page 59: Approach to Milestone Regression

Onset in late infancy• Hypotonia initially• Peripheral neuropathy• Dysarthria • Optic atrophy• Mental regression• Decorticate posture

finally Expected life span ~ 3.5

years after onset of symptoms but can be as long > 10 years

Onset at 5-10 yr• Deterioration in school

performance• Alteration in personality• Incontinence• Seizures• Incoordination, Dysarthria• Gait disturbances• Spasticity• No peripheral neuropathy• Slow progression• Spastic quadriplegia

eventually • Death usually during 2nd decade.

Page 60: Approach to Milestone Regression

Life-threatening disorder deficiency of a peroxisomal acyl coenzyme A synthetase. occurring in males, affects white matter & adrenal gland. Very long chain fatty acids accumulate in the cells & tissues

causing myelin sheath damage as well as dysfunction of the adrenal gland.

X-linked form is the commonest

Diagnosis is made by estimation of very long-chain fatty acids in plasma

Adrenoleucodystrophy

Page 61: Approach to Milestone Regression

Neuronal ceroid lipofuscinosis AR Storage of auto fluorescent hydrophobic material in

lysosomes of neurons & other tissue 3 subtypes – Infantile / Late infantile / Juvenile

Symptoms/ Signs◦Myoclonic jerks , seizures (5-9 years)◦Visual symptoms◦ Cerebellar ataxia◦ Cognitive decline (5-9 years)◦ Pigmentary abnormalities in retina (4-5 years)

Page 62: Approach to Milestone Regression

Neuronal Ceroid Lipofuscinosis

Mean age of survival = 10 yrs Investigation Skin biopsy: ◦Ultra structural abnormalities- characteristic Finger-print

bodies Cortical biopsy:◦Distended neurons – characteristic Finger-print bodies◦ Staining for ceroid & lipofuscinosis

Treatment – symptomatic

Page 63: Approach to Milestone Regression

Zellweger syndrome : dysmorphic features &severe

psychomotor retardation, sensory neuronal deafness,

peripheral neuropathy & hepatocellular degeneration.

Diagnosed by demonstrating the elevated very long chain

fatty acids, pipecolic acid and bile and derivatives.

Peroxysomal disorders

Page 64: Approach to Milestone Regression

Females affected only Mutations in the gene encoding methyl-CpG-binding protein-2,

located on chromosome Xq28 Normal during 1st year Initial features - deceleration of head growth leading to

microcephaly, lack of interest in the environment & hypotonia. Followed by rapid developmental regression characterized by

loss of language skills, gait ataxia, seizures, and autistic behavior.

Characteristic feature - loss of purposeful hand movements before the age of 3.

Stereotyped activity develops that looks like hand wringing or washing.

Rett syndrome

Page 65: Approach to Milestone Regression

Rett syndrome Repetitive blows to the face – another stereotyped hand

movement. Following the initial rapid progression - continued slower

progression of neurological deterioration. Spastic paraparesis and quadriparesis - frequent endpoints. Dementia is usually severe. Stimulation produces an exaggerated stereotyped reaction

consisting of jerking movements of the trunk and limbs with episodes of disorganized breathing and apnea followed by hyperpnea.

Page 66: Approach to Milestone Regression

Rett syndrome Seizures - most children before age 3 years. After the period of rapid deterioration, the disease becomes

relatively stable, but dystonia may develop later. Patients usually survive into early adulthood An increased incidence of sudden, unexplained death.

Diagnosis - Clinical features & molecular genetic testing. Management - Supportive.

Page 67: Approach to Milestone Regression

Wilson’s disease

ARDegenerative disease of basal gangliaInborn error of copper metabolism

Academic deteriorationBehavioral changes , Dysarthria ,DysphasiaDrooling , Dystonia

K F ring

Page 68: Approach to Milestone Regression

Acquired Immunodeficiency Syndrome Encephalopathy

• Human retroviral disease (Lentivirus subfamily)• Transplacental or perinatal transmission of HIV from mothers• Breast-feeding • The mother may be asymptomatic when the child becomes

infected.• Evidence of infection is apparent during the first year in 30%

of children born to AIDS-infected mothers.• Outcome is worse when the onset of symptoms is early, and

the rate of progression in the child relates directly to the severity of disease in the mother.

• 20% children present with severe symptoms or die in infancy.

Page 69: Approach to Milestone Regression

Acquired Immunodeficiency Syndrome Encephalopathy

• The spectrum of neurological and non-neurological manifestations in HIV-infected children is somewhat different from that of adults.

• Hepatosplenomegaly and bone marrow failure, lymphocytic interstitial pneumonia, chronic diarrhea and failure to thrive, acquired microcephaly, cerebral vasculopathy, and basal ganglia calcification occur more frequently in children.

• Opportunistic infections (e.g., cerebral toxoplasmosis, progressive multifocal leukoencephalopathy) are rare in infants.

Page 70: Approach to Milestone Regression

Acquired Immunodeficiency Syndrome Encephalopathy

• AIDS encephalopathy - subacute or indolent• Not necessarily associated with failure to thrive or

opportunistic infections.• Onset of encephalopathy may occur from 2 months to 5 years

after exposure to the virus. • 90 % affected infants show symptoms by 18 months of age.• Progressive loss of developmental milestones, microcephaly,

dementia, and spasticity characterize the encephalopathy. • Other features (< 50% cases) - ataxia, pseudobulbar palsy,

involuntary movement disorders, myoclonus, and seizures.• Death usually occurs a few months after the onset of AIDS

encephalopathy.

Page 71: Approach to Milestone Regression

Acquired Immunodeficiency Syndrome Encephalopathy

• DNA PCR - preferred method for the diagnosis in infants and children > 18 months of age.

• Combined treatment with zidovudine (azidothymidine), didanosine, and nevirapine is well tolerated and may have sustained efficacy against HIV-1.

Page 72: Approach to Milestone Regression

Form of chronic measles encephalitis In a nonimmunized population, the average age at onset is 8

years. As a rule, children have experienced natural infection with the

rubeola virus at an early age, half of them before age 2 years.

First symptoms - Personality change and declining school performance.

Personality change - aggressive behavior or withdrawal.

Subacute Sclerosing Panencephalitis (SSPE)

Page 73: Approach to Milestone Regression

• Retinal examination during early stage shows pigmentary changes in the macula.

• Generalized seizures, usually myoclonic, develop next.

• EEG - characteristic pattern of periodic bursts of spike-wave complexes (approximately every 5–7 sec) occurring synchronously with the myoclonic jerk.

• After the onset of seizures, the child shows rapid neurological deterioration characterized by spasticity, dementia, and involuntary movements.

• Within 1 to 6 years from the onset of symptoms, the child is in a chronic vegetative state.

Page 74: Approach to Milestone Regression

• Diagnosis – demonstration of an increased antibody titre, usually associated with increased g –globulin concentrations, in the CSF.

• Intraventricular interferon-alfa combined with oral isoprinosine, 100 mg/kg/day.

• Repeat courses up to six times at 2- to 6-month intervals.

Page 75: Approach to Milestone Regression

THANK YOU

Page 76: Approach to Milestone Regression

REFERENCES

• Bradley’s Neurology in clinical practice 6th edition• Adams & Victor’s Principles of Neurology 10th edition• Fenichel’s Clinical Pediatric Neurology 7th edition

Page 77: Approach to Milestone Regression

COST OF VARIOUS TESTS AT DNA LABS INDIA

Page 78: Approach to Milestone Regression
Page 79: Approach to Milestone Regression